BRAF and lung carcinoma: Similarly, in lung cancer cells with mutant EGFR and BRAF, Krall et al. also reported that loss of KEAP1 (Kelch-like ECH associated protein 1) diminished the therapeutic effects of EGFR, BRAF and MEK inhibitors, indicating that KEAP1 is a biomarker to predict the responses of these inhibitors (192).